Despite a slight revenue dip, Hansa Biopharma AB (FRA:24H) strengthens its European presence and prepares for a significant U.S. market opportunity.

Despite a significant revenue drop, Hansa Biopharma AB (HNSBF) focuses on strategic financial moves and market expansion to bolster future growth.

The recent SEK 8 trim to the Hansa Biopharma price target, to SEK 69, sits alongside an unchanged fair value estimate of SEK 80.83, putting fresh attention on how risk is being priced in. That shift reflects a split in analyst views, with optimism around imlifidase milestones balanced against concerns about commercialization, regulatory timing, and potential reshaping of EU operations. Read on to see how these moving pieces shape the evolving Hansa Biopharma story and what to watch next. Stay...

Despite impressive revenue growth and strategic advancements, Hansa Biopharma AB faces market challenges and rising operational costs.

Wedbush initiated coverage of Hansa Biopharma (HNSBF) with an Outperform rating and SEK 69 price target The firm views Hansa Biopharma as a compelling, de-risked commercial story spanning organ transplants, autoimmune disease, and gene therapy. Lead asset imlifidase is already approved in Europe for desensitization of highly sensitized kidney transplant patients and is poised to become the first FDA-approved therapy in this setting, supported by positive Phase 3 ConfIdeS data and a BLA submissio

Hansa Biopharma (OM:HNSA) remains unprofitable, with net losses accelerating at an average rate of 11.5% per year over the last five years. Yet, revenue is projected to soar by 48.4% annually, far above the Swedish market’s 3.8% rate. Analysts expect earnings to climb 73.86% per year and tip into profitability within three years, a pace considered above average. For investors, the strong outlook for revenue and earnings growth offers a compelling story, but this is counterbalanced by the...